Literature DB >> 22176427

Minimally invasive lateral approach for symptomatic thoracic disc herniation: initial multicenter clinical experience.

Juan S Uribe1, William D Smith, Luiz Pimenta, Roger Härtl, Elias Dakwar, Urvij M Modhia, Glen A Pollock, Vamsi Nagineni, Ryan Smith, Ginger Christian, Leonardo Oliveira, Luis Marchi, Vedat Deviren.   

Abstract

OBJECT: Symptomatic herniated thoracic discs remain a surgical challenge and historically have been associated with significant complications. While neurological outcomes have improved with the abandonment of decompressive laminectomy, the attempt to minimize surgical complications and associated morbidities continues through less invasive approaches. Many of these techniques, such as thoracoscopy, have not been widely adopted due to technical difficulties. The current study was performed to examine the safety and early results of a minimally invasive lateral approach for symptomatic thoracic herniated intervertebral discs.
METHODS: Sixty patients from 5 institutions were treated using a mini-open lateral approach for 75 symptomatic thoracic herniated discs with or without calcification. The mean age was 57.9 years (range 23-80 years), and 53.3% of the patients were male. Treatment levels ranged from T4-5 to T11-12, with 1-3 levels being treated (mean 1.3 levels). The most common levels treated were T11-12 (14 cases [18.7%]), T7-8 (12 cases [16%]), and T8-9 (12 cases [16%]). Symptoms included myelopathy in 70% of cases, radiculopathy in 51.7%, axial back pain in 76.7%, and bladder and/or bowel dysfunction in 26.7%. Instrumentation included an interbody spacer in all but 6 cases (10%). Supplemental internal fixation included anterolateral plating in 33.3% of cases and pedicle screws in 10%; there was no supplemental internal fixation in 56.7% of cases. Follow-up ranged from 0.5 to 24 months (mean 11.0 months).
RESULTS: The median operating time, estimated blood loss, and length of stay were 182 minutes, 290 ml, and 5.0 days, respectively. Four major complications occurred (6.7%): pneumonia in 1 patient (1.7%); extrapleural free air in 1 patient (1.7%), treated with chest tube placement; new lower-extremity weakness in 1 patient (1.7%); and wound infection in posterior instrumentation in 1 patient (1.7%). Reoperations occurred in 3 cases (5%): one for posterior reexploration, one for infection in posterior instrumentation, and one for removal of symptomatic residual disc material. Back pain, measured using the visual analog scale, improved 60% from the preoperative score to the last follow-up, that is, from 7.8 to 3.1. Excellent or good overall outcomes were achieved in 80% of the patients, a fair or unchanged outcome resulted in 15%, and a poor outcome occurred in 5%. Moreover, myelopathy, radiculopathy, axial back pain, and bladder and/or bowel dysfunction improved in 83.3%, 87.0%, 91.1%, and 87.5% of cases, respectively.
CONCLUSIONS: The authors' early experience with a large multicenter series suggested that the minimally invasive lateral approach is a safe, reproducible, and efficacious procedure for achieving adequate decompression in thoracic disc herniations in a less invasive manner than conventional surgical techniques and without the use of endoscopes. Symptom resolution was achieved at similar rates using this approach as compared with the most efficacious techniques in the literature, and with fewer complications in most circumstances.

Entities:  

Mesh:

Year:  2011        PMID: 22176427     DOI: 10.3171/2011.10.SPINE11291

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  25 in total

1.  Transforaminal thoracic interbody fusion : Treatment of thoracic myelopathy caused by anterior compression.

Authors:  Ling-Jia Yu; Wen-Jing Li; Shi-Gong Guo; Yu Zhao
Journal:  Orthopade       Date:  2018-12       Impact factor: 1.087

Review 2.  MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.

Authors:  Jeff A Lehmen; Edward J Gerber
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

3.  Calcified giant thoracic disc herniations: considerations and treatment strategies.

Authors:  N A Quraishi; A Khurana; M M Tsegaye; B M Boszczyk; S M H Mehdian
Journal:  Eur Spine J       Date:  2014-02-12       Impact factor: 3.134

4.  Transthoracic lateral retropleural minimally invasive microdiscectomy for T9-T10 disc herniation.

Authors:  Pedro Berjano; Diego Garbossa; Marco Damilano; Matteo Pejrona; Roberto Bassani; Carlo Doria
Journal:  Eur Spine J       Date:  2014-06       Impact factor: 3.134

5.  Anterior thoracic foraminotomy through mini-thoracotomy for the treatment of giant thoracic disc herniations.

Authors:  Antonino Russo; G Balamurali; Robert Nowicki; Bronek Maximilian Boszczyk
Journal:  Eur Spine J       Date:  2012-03-20       Impact factor: 3.134

6.  Revision surgery in thoracic disc herniation.

Authors:  Stephan Dützmann; Roli Rose; Daniel Rosenthal
Journal:  Eur Spine J       Date:  2019-11-16       Impact factor: 3.134

7.  Risk factors associated with post-operative neurological deterioration in patients with thoracic disc disorders with myelopathy.

Authors:  Lei Yuan; Zhongqiang Chen; Weishi Li; Chuiguo Sun; Zhongjun Liu; Xiaoguang Liu
Journal:  Int Orthop       Date:  2021-04-07       Impact factor: 3.075

8.  Treatment of symptomatic thoracic disc herniations with lateral interbody fusion.

Authors:  Gregory M Malham; Rhiannon M Parker
Journal:  J Spine Surg       Date:  2015-12

9.  Giant central thoracic disc herniations: surgical outcome in 17 consecutive patients treated by mini-thoracotomy.

Authors:  Roland Roelz; Christoph Scholz; Jan-Helge Klingler; Christian Scheiwe; Ronen Sircar; Ulrich Hubbe
Journal:  Eur Spine J       Date:  2016-01-22       Impact factor: 3.134

10.  Surgical treatment of thoracic disc disease via minimally invasive lateral transthoracic trans/retropleural approach: analysis of 33 patients.

Authors:  Osman Arikan Nacar; Mustafa Onur Ulu; Murat Pekmezci; Vedat Deviren
Journal:  Neurosurg Rev       Date:  2013-04-10       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.